We partner with the media to inform the public of the global human crisis.
April 20, 2018Indivior Announces New Drug Submission to Health Canada for SUBLOCADE™ (Buprenorphine Extended-Release) Injection for the Treatment of Moderate to Severe Opioid Use Disorder...
April 13, 2018Patient-Reported Outcomes Data on SUBLOCADEᵀᴹ (Buprenorphine Extended-Release) Injection to be Presented as Late-Breaker at American Society of Addiction Medicine (ASAM) 49ᵗʰ Annual Conference...
April 11, 2018Indivior to Announce First Quarter 2018 Results on May 2nd and Host Conference Call...
April 5, 2018Indivior Files Complaints Asserting New SUBOXONE® Film Patent Against ANDA-filers...
March 29, 2018Indivior Enters Into an Exclusive Global License Agreement for C4X Discovery’s Orexin-1 (OX1) Antagonist Program...
Global Media Contacts
The Online Press Kit is designed to help media research our company for background information or follow-up stories. Please visit the links below to learn more.
About Indivior PLC – An overview of Indivior, including our worldwide locations and key products
Board of Directors – Biographies of Indivior’s Board
The Indivior PLC Pipeline – Information about the Indivior R&D efforts and progress of medicines in the pipeline